Evaluation of See.d as an Automated Blood Sample Preparator for Multiple Liquid Biopsy Applications

Inclusion Criteria

• •General (all participants)
• •* Participants is willing and able to give and sign a written informed consent
• •* Aged 18 or above
• •Specific for metastatic breast cancer patients
• •* Female for metastatic breast cancer patients, aged 18 or above
• •* Histological confirmation of breast cancer
• •* Presence of at least one non-bone metastasis
• •* Disease assessed to be in clinical or radiologic progression to the last line of treatment, as evaluated by the investigator
• •* The biopsy, when recommended by the oncologist, is scheduled within 4 weeks after the date of blood withdrawal
• •* Last biopsy or any other minor surgical procedure was perfomed at least 7 days before blood withdrawal
• •* Known Bilirubin level ≥ 2 mg/dL on a blood sample collected within 7 days from the enrolment. If unavailable, it is not necessary to assess bilirubin
• •Specific for healthy participants
• •* Both sexes for healthy volunteers, aged 18 or above
• •* Healthy participants who visit the site for reason other than cancer diagnosis (including breast cancer).